Advertisement
Canada markets closed
  • S&P/TSX

    21,554.86
    -26.49 (-0.12%)
     
  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     
  • DOW

    39,150.33
    +15.57 (+0.04%)
     
  • CAD/USD

    0.7304
    -0.0003 (-0.04%)
     
  • CRUDE OIL

    80.59
    -0.70 (-0.86%)
     
  • Bitcoin CAD

    87,808.08
    -727.98 (-0.82%)
     
  • CMC Crypto 200

    1,325.98
    -34.35 (-2.53%)
     
  • GOLD FUTURES

    2,334.70
    -34.30 (-1.45%)
     
  • RUSSELL 2000

    2,022.03
    +4.64 (+0.23%)
     
  • 10-Yr Bond

    4.2570
    +0.0030 (+0.07%)
     
  • NASDAQ

    17,689.36
    -32.23 (-0.18%)
     
  • VOLATILITY

    13.20
    -0.08 (-0.60%)
     
  • FTSE

    8,237.72
    -34.74 (-0.42%)
     
  • NIKKEI 225

    38,596.47
    -36.55 (-0.09%)
     
  • CAD/EUR

    0.6826
    +0.0005 (+0.07%)
     

Enfusion First Quarter 2024 Earnings: EPS Misses Expectations

Enfusion (NYSE:ENFN) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$48.1m (up 17% from 1Q 2023).

  • Net loss: US$539.0k (down by 117% from US$3.17m profit in 1Q 2023).

  • US$0.006 loss per share (down from US$0.036 profit in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Enfusion EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates.

Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Software industry in the US.

ADVERTISEMENT

Performance of the American Software industry.

The company's shares are down 5.4% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Enfusion you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.